COSCIENS Biopharma Inc.
AEZS
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.38M
Close$
$3.61
36.9% downside
Current Fair Value
36.9% downsideOvervalued by 36.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.38 Million |
|---|---|
| Enterprise Value | $22.07 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.65 |
| Beta | 2.26 |
| Outstanding Shares | 2,220,303 |
Return
| Return on Equity | -32.16% |
|---|---|
| Return on Assets | -25.32% |
| Return on Invested Capital | -27.13% |
Valuation & Multiples
| P/E Ratio | -0.52 |
|---|---|
| PEG | 0.56 |
| Price to Sales | 1.91 |
| Price to Book Ratio | 0.95 |
| Enterprise Value to Revenue | 2.67 |
| Enterprise Value to EBIT | -4.91 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aeterna Zentaris Inc.
28 employees
CEO: Klaus Paulini Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved ora...